Vermillion Q4 Revenues Spike 45 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market on Thursday that its fourth quarter revenues grew 45 percent year over year on an increase in revenues generated by its OVA1 ovarian cancer test.

For the three months ended Dec. 31, 2013, the Austin, Texas-based company recorded $1.6 million in total revenues, up from $1.1 million in the year-ago period. Product revenues, comprised of OVA1 sales, rose to $1.5 million from $1.0 million, while licensing revenues were flat at $113,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: system to track intron gains and losses, role of RUNX during mitosis, and more.

French officials release a report and move to strength safety measures for clinical trials, ScienceInsider reports.

Researchers find different molecular signatures in cancers from men as compared to those from women, the Wall Street Journal reports.

Researchers trace the deaths of a pair of newborn siblings to a mutation in their LIPT1 genes through whole-exome sequencing, Stat News reports.